AAPL339.50-3.44 (-1.00%) ▼|ABBV289.08+6.40 (+2.26%) ▲|ABT102.70-1.36 (-1.31%) ▼|ACN239.21+2.28 (+0.96%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.62+0.59 (+0.32%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.41+2.00 (+0.63%) ▲|BA190.39-1.03 (-0.54%) ▼|BAC50.66+0.27 (+0.54%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.55+3.95 (+0.35%) ▲|BMY61.72+2.89 (+4.90%) ▲|BNY144.26+1.82 (+1.27%) ▲|BRK-B540.18+7.95 (+1.49%) ▲|C122.53+0.84 (+0.69%) ▲|CAT725.47-0.32 (-0.04%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.58+1.75 (+0.88%) ▲|COP145.97+0.73 (+0.50%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.44-0.01 (0.00%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.71+2.03 (+2.19%) ▲|CVX225.78+1.41 (+0.63%) ▲|DE632.54+5.54 (+0.88%) ▲|DHR224.02-0.41 (-0.18%) ▼|DIS111.66+2.07 (+1.88%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.48-0.07 (-0.04%) ▼|FDX298.76+4.98 (+1.69%) ▲|GD344.48+3.05 (+0.89%) ▲|GE299.92-11.36 (-3.65%) ▼|GEV890.50-17.94 (-1.97%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.10-5.65 (-6.83%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.99+9.21 (+1.05%) ▲|HD315.16+5.28 (+1.70%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM242.02+5.63 (+2.38%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.42+5.63 (+2.22%) ▲|JPM335.45+1.92 (+0.58%) ▲|KO93.51+0.09 (+0.09%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,284.88+44.54 (+3.59%) ▲|LMT548.87+0.64 (+0.12%) ▲|LOW198.58+2.66 (+1.36%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.52+4.12 (+0.67%) ▲|MCD246.54+3.87 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.67+1.90 (+2.05%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.44+9.43 (+5.82%) ▲|MO74.63+0.54 (+0.73%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.43+1.96 (+1.10%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.89+0.72 (+0.92%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.89+0.68 (+1.83%) ▲|NOW149.58+4.22 (+2.90%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.09+1.50 (+1.16%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG159.38+1.69 (+1.07%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.93-1.12 (-0.56%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.83+8.45 (+1.24%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|AAPL339.50-3.44 (-1.00%) ▼|ABBV289.08+6.40 (+2.26%) ▲|ABT102.70-1.36 (-1.31%) ▼|ACN239.21+2.28 (+0.96%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.62+0.59 (+0.32%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.41+2.00 (+0.63%) ▲|BA190.39-1.03 (-0.54%) ▼|BAC50.66+0.27 (+0.54%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.55+3.95 (+0.35%) ▲|BMY61.72+2.89 (+4.90%) ▲|BNY144.26+1.82 (+1.27%) ▲|BRK-B540.18+7.95 (+1.49%) ▲|C122.53+0.84 (+0.69%) ▲|CAT725.47-0.32 (-0.04%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.58+1.75 (+0.88%) ▲|COP145.97+0.73 (+0.50%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.44-0.01 (0.00%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.71+2.03 (+2.19%) ▲|CVX225.78+1.41 (+0.63%) ▲|DE632.54+5.54 (+0.88%) ▲|DHR224.02-0.41 (-0.18%) ▼|DIS111.66+2.07 (+1.88%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.48-0.07 (-0.04%) ▼|FDX298.76+4.98 (+1.69%) ▲|GD344.48+3.05 (+0.89%) ▲|GE299.92-11.36 (-3.65%) ▼|GEV890.50-17.94 (-1.97%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.10-5.65 (-6.83%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.99+9.21 (+1.05%) ▲|HD315.16+5.28 (+1.70%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM242.02+5.63 (+2.38%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.42+5.63 (+2.22%) ▲|JPM335.45+1.92 (+0.58%) ▲|KO93.51+0.09 (+0.09%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,284.88+44.54 (+3.59%) ▲|LMT548.87+0.64 (+0.12%) ▲|LOW198.58+2.66 (+1.36%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.52+4.12 (+0.67%) ▲|MCD246.54+3.87 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.67+1.90 (+2.05%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.44+9.43 (+5.82%) ▲|MO74.63+0.54 (+0.73%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.43+1.96 (+1.10%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.89+0.72 (+0.92%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.89+0.68 (+1.83%) ▲|NOW149.58+4.22 (+2.90%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.09+1.50 (+1.16%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG159.38+1.69 (+1.07%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.93-1.12 (-0.56%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.83+8.45 (+1.24%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|
19.1 C
New York
Tuesday, October 20, 2026

Tag: therapies

newsFORsourcecompanycontentinformation1releasesmarket

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it...

ProBio and GCP ClinPlus Partner to Accelerate Clinical Trials in China

ProBio and GCP ClinPlus today announced a strategic collaboration designed to accelerate Investigator-Initiated Trials (IITs) in China and provide integrated, end-to-end clinical and development...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

Levicept to Present Data Suggesting LEVI-04 May Modify Disease in Osteoarthritis at EULAR 2026

Further clinical efficacy and pharmacology data also to be presented 
Further clinical efficacy and pharmacology data also to be presented

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated...

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026...

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results -

Crescent Biopharma to Present at June Investor Conferences

WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in June:

Demand for Compounding Pharmacies in USA to Reach USD 12.79 Billion by 2036 Amid Growing Need for Personalized Therapies and Specialized Medication Solutions

NEWARK, Del., June 2, 2026 /PRNewswire/ -- The Demand for Compounding Pharmacies in USA is projected to grow from USD 6.04 billion in 2026 to...

Kroger Health, along with Hy-Vee, Convenes Industry Leaders to Shape the Future of Health at Nourishing Change Conference

As chronic disease, GLP-1 adoption, and food for health reshape American healthcare, Kroger Health gathers leaders to explore the grocery store's emerging role as...

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising...

Defiance Launches the First Autism-Impact ETF (Ticker: ASD), Donating Profits to Autism Causes *

Defiance Launches the First Autism-Impact ETF (Ticker: ASD), Donating Profits to Autism Causes

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed...

The Ensign Group Acquires Real Estate and Operations in Iowa

SAN JUAN CAPISTRANO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it acquired the real estate and operations of “Woodland Health and Rehabilitation,” a 62-bed skilled nursing facility located in Mount Pleasant, Iowa. The real estate was acquired by a subsidiary of Standard Bearer Healthcare REIT, Inc., Ensign’s captive real estate company, and the facility is operated by an Ensign-affiliated tenant. The acquisition was effective as of June 1, 2026.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapies

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers